| Parameter . | Group 1 . | . | Group 2 . | ||
|---|---|---|---|---|---|
| Ly5.1+: untreated; Ly5.2+: untreated . | P-value . | Ly5.1+: untreated; Ly5.2+: TAT–Bcl-xL . | P-value . | ||
| BM | |||||
| Cells (×107) | 3.58 ± 0.48 | 3.83 ± 3.22 | |||
| Monocytes (×106) | 4.88 ± 1.05 | 4.64 ± 0.79 | |||
| Granulocytes (×106) | 10.4 ± 1.9 | 1,000 ± 110 | |||
| B220+IgM− B cells (×106) | 2.86 ± 0.46 | 3.81 ± 0.34 | |||
| IgM+ B cells (×106) | 2.21 ± 0.42 | 2.60 ± 0.34 | |||
| CD4+ T cells (×106) | 0.34 ± 0.05 | 0.47 ± 0.05 | |||
| CD8+ T cells (×106) | 0.62 ± 0.09 | 0.71 ± 0.10 | |||
| Ly5.1+ monocytes (%) | 29.64 ± 7.65 | 0.28 | 20.93 ± 8.50 | 0.03 | |
| Ly5.2+ monocytes (%) | 44.25 ± 8.85 | 63.32 ± 10.70 | |||
| Ly5.1+ granulocytes (%) | 33.32 ± 6.20 | 0.65 | 21.24 ± 7.35 | 0.05 | |
| Ly5.2+ granulocytes (%) | 40.24 ± 8.13 | 59.29 ± 11.03 | |||
| Ly5.1+ B220+IgM− cells (%) | 36.26 ± 6.41 | 0.80 | 14.37 ± 6.78 | 0.02 | |
| Ly5.2+ B220+IgM− cells (%) | 35.87 ± 7.59 | 63.61 ± 8.45 | |||
| Ly5.1+ B220+IgM+ cells (%) | 44.41 ± 5.10 | 0.58 | 17.40 ± 7.41 | 0.04 | |
| Ly5.2+ B220+IgM+ cells (%) | 33.87 ± 5.89 | 64.61 ± 7.72 | |||
| Ly5.1+ CD4+ cells (%) | 22.79 ± 2.95 | 0.72 | 10.81 ± 2.75 | 0.006 | |
| Ly5.2+ CD4+ cells (%) | 21.77 ± 3.64 | 38.55 ± 3.83 | |||
| Ly5.1+ CD8+ cells (%) | 31.45 ± 2.43 | 0.01 | 16.40 ± 4.34 | 0.11 | |
| Ly5.2+ CD8+ cells (%) | 16.21 ± 2.17 | 31.01 ± 3.98 | |||
| Spleen | |||||
| Cells (×107) | 11.70 ± 0.86 | 12.29 ± 0.73 | |||
| Monocytes (×106) | 4.36 ± 0.85 | 2.88 ± 0.38 | |||
| Granulocytes (×106) | 2.68±0.43 | 1.76±0.25 | |||
| B220+IgM− B cells (×106) | 30.5±9.3 | 35.2±7.1 | |||
| IgM+ B cells (×106) | 37.7 ± 6.1 | 39.2±6.4 | |||
| CD4+ T cells (×106) | 19.7 ± 2.0 | 19.3±1.6 | |||
| CD8+ T cells (×106) | 9.89 ± 0.69 | 9.27±0.62 | |||
| Thymus | |||||
| Cells (×107) | 6.86 ± 0.84 | 4.64 ± 0.86 | |||
| DN cells (×106) | 1.86 ± 0.51 | 2.12 ± 0.63 | |||
| DP cells (×106) | 49.3 ± 6.4 | 31.0 ± 6.9 | |||
| CD4+ SP cells (×106) | 5.66 ± 1.09 | 4.68 ± 0.95 | |||
| CD8+ SP cells (×106) | 3.46 ± 1.26 | 2.37 ± 0.49 | |||
| Ly5.1+ DN cells (%) | 48.93 ± 6.77 | 0.11 | 21.54 ± 6.39 | 0.05 | |
| Ly5.2+ DN cells (%) | 27.26 ± 7.37 | 55.24 ± 8.51 | |||
| Ly5.1+ DP cells (%) | 60.36 ± 12.24 | 0.14 | 25.28 ± 10.85 | 0.08 | |
| Ly5.2+ DP cells (%) | 24.80 ± 10.56 | 63.75 ± 11.49 | |||
| Ly5.1+ CD4+ SP cells (%) | 65.47 ± 9.92 | 0.08 | 26.22 ± 10.13 | 0.08 | |
| Ly5.2+ CD4+ SP cells (%) | 27.34 ± 9.31 | 64.46 ± 10.33 | |||
| Ly5.1+ CD8+ SP cells (%) | 54.04 ± 10.81 | 0.33 | 17.74 ± 8.23 | 0.02 | |
| Ly5.2+ CD8+ SP cells (%) | 36.31 ± 9.87 | 70.23 ± 10.26 | |||
| Blood | |||||
| Cells (/µl) | 10,755 ± 895 | 10,391 ± 799 | |||
| Monocytes (/µl) | 616 ± 78 | 422 ± 62 | |||
| Granulocytes (/µl) | 970 ± 111 | 685 ± 99 | |||
| B220+IgM− B cells (/µl) | 3,821 ± 822 | 3,562 ± 560 | |||
| IgM+ B cells (/µl) | 1,845 ± 437 | 2,188 ± 502 | |||
| CD4+ T cells (/µl) | 1,803 ± 178 | 1,746 ± 135 | |||
| CD8+ T cells (/µl) | 1,073 ± 103 | 1,006 ± 77 | |||
| Ly5.1+ monocytes (%) | 46.34 ± 8.69 | 0.65 | 27.44 ± 9.23 | 0.11 | |
| Ly5.2+ monocytes (%) | 38.05 ± 8.96 | 60.49 ± 9.36 | |||
| Ly5.1+ granulocytes (%) | 45.74 ± 6.60 | 0.39 | 29.14 ± 8.58 | 0.18 | |
| Ly5.2+ granulocytes (%) | 38.28 ± 7.59 | 56.30 ± 9.90 | |||
| Ly5.1+ B220+IgM− cells (%) | 45.24 ± 5.19 | 0.88 | 21.64 ± 8.10 | 0.03 | |
| Ly5.2+ B220+IgM− cells (%) | 38.42 ± 6.10 | 66.00 ± 8.74 | |||
| Ly5.1+ B220+IgM+ cells (%) | 38.33 ± 4.94 | 0.96 | 18.24 ± 7.46 | 0.02 | |
| Ly5.2+ B220+IgM+ cells (%) | 34.51 ± 5.38 | 60.74 ± 8.12 | |||
| Ly5.1+ CD4+ cells (%) | 56.86 ± 4.88 | 0.02 | 29.47 ± 8.29 | 0.18 | |
| Ly5.2+ CD4+ cells (%) | 23.67 ± 4.84 | 49.59 ± 8.13 | |||
| Ly5.1+ CD8+ cells (%) | 45.71 ± 3.43 | 0.01 | 23.69 ± 5.43 | 0.11 | |
| Ly5.2+ CD8+ cells (%) | 19.22 ± 3.14 | 37.96 ± 5.71 | |||
| Parameter . | Group 1 . | . | Group 2 . | ||
|---|---|---|---|---|---|
| Ly5.1+: untreated; Ly5.2+: untreated . | P-value . | Ly5.1+: untreated; Ly5.2+: TAT–Bcl-xL . | P-value . | ||
| BM | |||||
| Cells (×107) | 3.58 ± 0.48 | 3.83 ± 3.22 | |||
| Monocytes (×106) | 4.88 ± 1.05 | 4.64 ± 0.79 | |||
| Granulocytes (×106) | 10.4 ± 1.9 | 1,000 ± 110 | |||
| B220+IgM− B cells (×106) | 2.86 ± 0.46 | 3.81 ± 0.34 | |||
| IgM+ B cells (×106) | 2.21 ± 0.42 | 2.60 ± 0.34 | |||
| CD4+ T cells (×106) | 0.34 ± 0.05 | 0.47 ± 0.05 | |||
| CD8+ T cells (×106) | 0.62 ± 0.09 | 0.71 ± 0.10 | |||
| Ly5.1+ monocytes (%) | 29.64 ± 7.65 | 0.28 | 20.93 ± 8.50 | 0.03 | |
| Ly5.2+ monocytes (%) | 44.25 ± 8.85 | 63.32 ± 10.70 | |||
| Ly5.1+ granulocytes (%) | 33.32 ± 6.20 | 0.65 | 21.24 ± 7.35 | 0.05 | |
| Ly5.2+ granulocytes (%) | 40.24 ± 8.13 | 59.29 ± 11.03 | |||
| Ly5.1+ B220+IgM− cells (%) | 36.26 ± 6.41 | 0.80 | 14.37 ± 6.78 | 0.02 | |
| Ly5.2+ B220+IgM− cells (%) | 35.87 ± 7.59 | 63.61 ± 8.45 | |||
| Ly5.1+ B220+IgM+ cells (%) | 44.41 ± 5.10 | 0.58 | 17.40 ± 7.41 | 0.04 | |
| Ly5.2+ B220+IgM+ cells (%) | 33.87 ± 5.89 | 64.61 ± 7.72 | |||
| Ly5.1+ CD4+ cells (%) | 22.79 ± 2.95 | 0.72 | 10.81 ± 2.75 | 0.006 | |
| Ly5.2+ CD4+ cells (%) | 21.77 ± 3.64 | 38.55 ± 3.83 | |||
| Ly5.1+ CD8+ cells (%) | 31.45 ± 2.43 | 0.01 | 16.40 ± 4.34 | 0.11 | |
| Ly5.2+ CD8+ cells (%) | 16.21 ± 2.17 | 31.01 ± 3.98 | |||
| Spleen | |||||
| Cells (×107) | 11.70 ± 0.86 | 12.29 ± 0.73 | |||
| Monocytes (×106) | 4.36 ± 0.85 | 2.88 ± 0.38 | |||
| Granulocytes (×106) | 2.68±0.43 | 1.76±0.25 | |||
| B220+IgM− B cells (×106) | 30.5±9.3 | 35.2±7.1 | |||
| IgM+ B cells (×106) | 37.7 ± 6.1 | 39.2±6.4 | |||
| CD4+ T cells (×106) | 19.7 ± 2.0 | 19.3±1.6 | |||
| CD8+ T cells (×106) | 9.89 ± 0.69 | 9.27±0.62 | |||
| Thymus | |||||
| Cells (×107) | 6.86 ± 0.84 | 4.64 ± 0.86 | |||
| DN cells (×106) | 1.86 ± 0.51 | 2.12 ± 0.63 | |||
| DP cells (×106) | 49.3 ± 6.4 | 31.0 ± 6.9 | |||
| CD4+ SP cells (×106) | 5.66 ± 1.09 | 4.68 ± 0.95 | |||
| CD8+ SP cells (×106) | 3.46 ± 1.26 | 2.37 ± 0.49 | |||
| Ly5.1+ DN cells (%) | 48.93 ± 6.77 | 0.11 | 21.54 ± 6.39 | 0.05 | |
| Ly5.2+ DN cells (%) | 27.26 ± 7.37 | 55.24 ± 8.51 | |||
| Ly5.1+ DP cells (%) | 60.36 ± 12.24 | 0.14 | 25.28 ± 10.85 | 0.08 | |
| Ly5.2+ DP cells (%) | 24.80 ± 10.56 | 63.75 ± 11.49 | |||
| Ly5.1+ CD4+ SP cells (%) | 65.47 ± 9.92 | 0.08 | 26.22 ± 10.13 | 0.08 | |
| Ly5.2+ CD4+ SP cells (%) | 27.34 ± 9.31 | 64.46 ± 10.33 | |||
| Ly5.1+ CD8+ SP cells (%) | 54.04 ± 10.81 | 0.33 | 17.74 ± 8.23 | 0.02 | |
| Ly5.2+ CD8+ SP cells (%) | 36.31 ± 9.87 | 70.23 ± 10.26 | |||
| Blood | |||||
| Cells (/µl) | 10,755 ± 895 | 10,391 ± 799 | |||
| Monocytes (/µl) | 616 ± 78 | 422 ± 62 | |||
| Granulocytes (/µl) | 970 ± 111 | 685 ± 99 | |||
| B220+IgM− B cells (/µl) | 3,821 ± 822 | 3,562 ± 560 | |||
| IgM+ B cells (/µl) | 1,845 ± 437 | 2,188 ± 502 | |||
| CD4+ T cells (/µl) | 1,803 ± 178 | 1,746 ± 135 | |||
| CD8+ T cells (/µl) | 1,073 ± 103 | 1,006 ± 77 | |||
| Ly5.1+ monocytes (%) | 46.34 ± 8.69 | 0.65 | 27.44 ± 9.23 | 0.11 | |
| Ly5.2+ monocytes (%) | 38.05 ± 8.96 | 60.49 ± 9.36 | |||
| Ly5.1+ granulocytes (%) | 45.74 ± 6.60 | 0.39 | 29.14 ± 8.58 | 0.18 | |
| Ly5.2+ granulocytes (%) | 38.28 ± 7.59 | 56.30 ± 9.90 | |||
| Ly5.1+ B220+IgM− cells (%) | 45.24 ± 5.19 | 0.88 | 21.64 ± 8.10 | 0.03 | |
| Ly5.2+ B220+IgM− cells (%) | 38.42 ± 6.10 | 66.00 ± 8.74 | |||
| Ly5.1+ B220+IgM+ cells (%) | 38.33 ± 4.94 | 0.96 | 18.24 ± 7.46 | 0.02 | |
| Ly5.2+ B220+IgM+ cells (%) | 34.51 ± 5.38 | 60.74 ± 8.12 | |||
| Ly5.1+ CD4+ cells (%) | 56.86 ± 4.88 | 0.02 | 29.47 ± 8.29 | 0.18 | |
| Ly5.2+ CD4+ cells (%) | 23.67 ± 4.84 | 49.59 ± 8.13 | |||
| Ly5.1+ CD8+ cells (%) | 45.71 ± 3.43 | 0.01 | 23.69 ± 5.43 | 0.11 | |
| Ly5.2+ CD8+ cells (%) | 19.22 ± 3.14 | 37.96 ± 5.71 | |||
The transplantation procedure and groups are defined in Fig. 5 D. Values represent means of n = 10–11 animals of three independent experiments ± SEM. Significant p-values with regard to the Ly5.1+/Ly5.2+ ratio are indicated (Wilcoxon test). DN, double negative; DP, double positive; SP, single positive.